Schizophrenia. Schizophrenia, schizotypal and delusional disorders
Conditions
Interventions
Intervention 1: Additive treatment with rivastigmin in intervention group, Rivastigmin 1.5 to 6 mg/ day in one to divided doses. Intervention 2: Addition of placebo instead of rivastigmin in control g
Treatment - Drugs
Placebo
Additive treatment with rivastigmin in intervention group, Rivastigmin 1.5 to 6 mg/ day in one to divided doses.
Addition of placebo instead of rivastigmin in control group
Sponsors
Kermanshah University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusive criteria: 1) the diagnosis of schizophrenia made by the psychiatrist based on DSM.IV.TR; 1) the presence of some cognitive deficits; 3) being volunteer to participate in the study; 4) being under treatment with atypical antipsychotic medications. Exclusion criteria: 1) disagreement to participate in the study; 2) treatment with typical antipsychotic agents; 3) absence of any of inclusive criteria; 4) concordance of substance dependence disorders; 5) co-morbidity with organic mental disorders.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive status. Timepoint: The week 0 and week 12. Method of measurement: MMSE questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of cognitive status. Timepoint: The weeks 0 and 12. Method of measurement: MMSE questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaezeh Tatari
Kermanshah University of Medical Sciences and Health Services
Outcome results
None listed